Costs of managing adverse events in the treatment of first-line metastatic renal cell carcinoma: Bevacizumab in combination with interferon-α2a compared with sunitinib

G. Mickisch, M. Gore, B. Escudier, G. Procopio, S. Walzer, M. Nuijten

Research output: Contribution to journalArticlepeer-review

Original languageEnglish
Pages (from-to)1303-1304
Number of pages2
JournalJournal of Urology
Issue number4
Publication statusPublished - Oct 2010

ASJC Scopus subject areas

  • Urology

Cite this